Oral corticosteroid dosage reduction sustained in open-label extension study of dupilumab
Your search for oral corticosteroids returned 24 results
Patients with normal adrenal function are largely able to eliminate the use of oral corticosteroids or achieve a daily dose of 5 mg or less.
Drug-induced immunosuppression, particularly from oral corticosteroids, may limit response to COVID-19 vaccine
A post-hoc analysis of the VENTURE trial evaluated whether baseline oral corticosteroid dosage affected the efficacy of dupilumab in improving severe asthma outcomes.
Long-term treatment of oral corticosteroid (OCS)-dependent asthma with dupilumab has shown efficacy in weaning off OCS while improving lung function.
Patients with flares more likely to have inpatient, emergency department visits
Zolgensma is an adeno-associated virus vector-based gene therapy.
The BLA submission is supported by data from the PATHFINDER clinical program.
NAVIGATOR trial results presented at CHEST 2021 show the effect of tezepelumab on peak expiratory flow rates in severe asthma.
The BLA submission included data from the pivotal phase 3 NAVIGATOR trial that assessed tezepelumab in 1061 patients with severe, uncontrolled asthma.